Hypoxic gene expression and metastasis

Cancer and Metastasis Reviews

Volumn 23, Issue 3-4, 2004, Pages 293-310

  Le, Quynh Thu ^a   Denko, Nicholas C ^a   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; apoptosis; CXCR4; ephrin; hypoxia; osteopontin

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPHRIN; OSTEOPONTIN;

ANGIOGENESIS; APOPTOSIS; CELL SURVIVAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HYPOXIA; METASTASIS; NONHUMAN; OXYGEN ELECTRODE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TISSUE REGENERATION;

ANIMALS; CELL HYPOXIA; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS;

EID: 3042854048     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CANC.0000031768.89246.d7     Document Type: Review

References (183)

1. Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416, 1998
2. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539-549, 1955
3. Kennedy KA, Teicher BA, Rockwell S, Sartorelli AC: The hypoxic tumor cell: A target for selective cancer chemotherapy. Biochem Pharmacol 29: 1-8, 1980
4. Harris AL: Hypoxia - a key regulatory factor in tumor growth. Nat Rev Cancer 2: 38-47, 2002
5. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831-838, 1988
6. Wendling P, Manz R, Thews G, Vaupel P: Heterogeneous oxygenation of rectal carcinomas in humans: A critical parameter for preoperative irradiation? Adv Exp Med Biol 180: 293-300, 1984
7. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45-50, 1993
8. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996
9. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP: Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20: 680-687, 2002
10. 2 ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings. Urology 60: 634-639, 2002
11. Rofstad EK, Sundfor K, Lyng H, Trope CG: Hypoxia-induced treatment failure in advanced squamous cell carci-noma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 83: 354-359, 2000
12. Brizel DM, Scully SP, Harrelson JM: Tumor oxygenation predicts for likelihood of distant metastasis in human soft tissue sarcoma. Cancer Res 56: 941-943, 1996
13. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, Overgaard J: Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. Br J Cancer 84: 1070-1075, 2001
14. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL: Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19: 3660-3668, 2001
15. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ: Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21: 473-482, 2003
16. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399, 2001
17. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, AL. H: Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 85: 881-890, 2001
18. Kaelin WG Jr.: How oxygen makes its presence felt. Genes Dev 16: 1441-1445, 2002
19. Giaccia A, Siim BG, Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2: 803-811, 2003
20. Taylor CT, Furuta GT, Synnestvedt K, Colgan SP: Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. Proc Natl Acad Sci USA 97: 12091-12096, 2000
21. Schmedtje JF Jr., Ji YS, Liu WL, DuBois RN, Runge MS: Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272: 601-608, 1997
22. Faller DV: Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 26: 74-84, 1999
23. Yan SF, Lu J, Zou YS, Soh-Won J, Cohen DM, Buttrick PM, Cooper DR, Steinberg SF, Mackman N, Pinsky DJ, Stern DM: Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 274: 15030-15040, 1999
24. Koong AC, Giaccia AJ: Hypoxia-mediated signaling pathways (Chapter 311). In Handbook of Cell Signaling. Bradshaw RA, Dennis EA, eds. Elsevier Science, 2003, pp. 277-281
25. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, Giaccia AJ: Candidate genes for the hypoxic tumor phenotype. Cancer Res 60: 883-887, 2000
26. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ: Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling. Oncogene 19: 6297-6305, 2000
27. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Altman SR, Giaccia AJ: Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22: 5907-5914, 2003
28. Scandurro AB, Weldon CW, Figueroa YG, Alam J, Beckman BS: Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells. Int J Oncol 19: 129-135, 2001
29. Kunz M, Moeller S, Koczan D, Lorenz P, Wenger RH, Glocker MO, Thiesen HJ, Gross G, Ibrahim SM: Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J Biol Chem 278: 45651-45660, 2003
30. Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ, Riggins GJ: Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93: 1337-1343, 2001
31. Yan SF, Zou YS, Gao Y, Zhai C, Mackman N, Lee SL, Milbrandt J, Pinsky D, Kisiel W, Stern D: Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci USA 95: 8298-8303, 1998
32. Postovit LM, Adams MA, Lash GE, Heaton JP, Graham CH: Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway. J Biol Chem 277: 35730-35737, 2002
33. Harbeck N, Kates RE, Look MP, Meijer-van Gelder ME, Klijn JG, Kruger A, Kiechle M, Janicke F, Schmitt M, Foekens JA: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3,424). Cancer Res 62: 4617-4622, 2002
34. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8,377 breast cancer patients. J Natl Cancer Inst 94: 116-128, 2002
35. Janicke F, Schmitt M, Ulm K, Gossner W, Graeff H: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 2: 1049, 1989
36. Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530, 1994
37. Dunbar SD, Ornstein DL, Zacharski LR: Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin. Expert Opin Investig Drugs 9: 2085-2092, 2000
38. Uetsuji S, Yamamura M, Takai S, Hioki K, Yamamoto M: Effect of aprotinin on metastasis of Lewis lung tumor in mice. Surg Today 22: 439-442, 1992
39. Monden T, Morimoto H, Shimano T, Yagyu T, Murotani M, Nagaoka H, Kawasaki Y, Kobayashi T, Mori T: Use of fibrinogen to enhance the antitumor effect of OK-432. A new approach to immunotherapy for colorectal carcinoma. Cancer 69: 636-642, 1992
40. Lentschener C, Benhamou D, Mercier FJ, Boyer-Neumann C, Naveau S, Smadja C, Wolf M, Franco D: Aprotinin reduces blood loss in patients undergoing elective liver resection. Anesth Analg 84: 875-881, 1997
41. Putnam JB, Royston D: Evaluating the role of serine protease inhibition in the management of tumor micro-metastases. Oncology (Huntingt) 17: 9-30; quiz 31-32, 2003
42. Weber GF: The metastasis gene osteopontin: A candidate target for cancer therapy. Biochim Biophys Acta 1552: 61-85, 2001
43. Liaw L, Birk DE, Ballas CB. Whitsitt JS, Davidson JM, Hogan BL: Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101: 1468-1478, 1998
44. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9: 59-67, 2003
45. Overgaard J, Nordsmark M, Alsner J, Eriksen JG, Nielsen TB, Lukacova S, Horsman MR: Plasma osteopontin (OPN) predicts hypoxia and response to the hypoxic sensitizer Nimorazole in radiotherapy of head and neck cancer. Results from the randomized DAHANCA 5 trial (poster # 474), European Society of Therapeutic Radiology and Oncology, 2003
46. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611, 1997
47. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF: Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79: 502-508, 1998
48. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79: 127-132, 1998
49. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y: Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 72: 55-63, 1995
50. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94: 513-521, 2002
51. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423, 2003
52. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127, 2003
53. Denhardt DT, Guo X: Osteopontin: A protein with diverse functions. Faseb J 7: 1475-1482, 1993
54. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF: Expression of antisense osteopontin RNA in metastatic mouse fibroblasts is associated with reduced malignancy. Ann N Y Acad Sci 760: 299-301, 1995
55. Wu Y, Denhardt DT, Rittling SR: Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83: 156-163, 2000
56. Crawford HC, Matrisian LM, Liaw L: Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 58: 5206-5215, 1998
57. Horuk R: Chemokine receptors. Cytokine Growth Factor Rev 12: 313-335, 2001
58. Murphy PM: Chemokines and the molecular basis of cancer metastasis. N Engl J Med 345: 833-835, 2001
59. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001
60. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832-1837, 2002
61. Robledo MM, Bartolome RA, Longo N, Rodriguez-Frade JM, Mellado M, Longo I, van Muijen GN, Sanchez-Mateos P, Teixido J: Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 276: 45098-45105, 2001
62. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, Ben-Baruch A: A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 167: 4747-4757, 2001
63. Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22: 8093-8101, 2003
64. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549, 2003
65. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumor suppressor pVHL. Nature 425: 307-311, 2003
66. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393: 595-599, 1998
67. Tachibana K, Hirota S, lizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, Kishimoto T, Nagasawa T: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393: 591-594, 1998
68. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, Nakashima H, Fujii N: A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140. Biochem Biophys Res Commun 253: 877-882, 1998
69. Tamamura H, Murakami T, Masuda M, Otaka A, Takada W, Ibuka T, Nakashima H, Waki M, Matsumoto A, Yamamoto N, et al.: Structure-activity relationships of an anti-HIV peptide, T22. Biochem Biophys Res Commun 205: 1729-1735, 1994
70. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, O'Brien WA: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 186: 1395-1400, 1997
71. Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186: 1383-1388, 1997
72. Trusolino L, Comoglio PM: Scatter-factor and semaphorin receptors: Cell signaling for invasive growth. Nat Rev Cancer 2: 289-300, 2002
73. Nakamura T, Teramoto H, Ichihara A: Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA 83: 6489-6493, 1986
74. Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, Kitamura N: Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373: 702-705, 1995
75. Takayama H, La Rochelle WJ, Anver M, Bockman DE, Merlino G: Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc Natl Acad Sci USA 93: 5866-5871, 1996
76. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C: Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373: 699-702, 1995
77. Miyazawa K, Shimomura T, Naka D, Kitamura N: Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem 269: 8966-8970, 1994
78. Yanagita K, Matsumoto K, Sekiguchi K, Ishibashi H, Niho Y, Nakamura T: Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J Biol Chem 268: 21212-21217, 1993
79. Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J: Met-HGF/SF: Tumorigenesis, invasion and metastasis. Ciba Found Symp 212: 119-130; discussion 130-112, 148-154, 1997
80. Comoglio PM, Trusolino L: Invasive growth: From development to metastasis. J Clin Invest 109: 857-862, 2002
81. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18: 2343-2350, 1999
82. Di Renzo MF, Olivero M, Marione T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19: 1547-1555, 2000
83. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S, et al.: Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1: 147-154, 1995
84. Di Renzo MF, Olivero M, Serini G, Orlandi F, Pilotti S, Belfiore A, Costantino A, Vigneri R, Angeli A, Pierotti MA, et al.: Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest 18: 134-139, 1995
85. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361, 2003
86. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C: K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21: 4885-4893, 2002
87. Bardelli A, Longati P, Williams TA, Benvenuti S, Comoglio PM: A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem 274: 29274-29281, 1999
88. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000
89. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237: 97-132, 1999
90. Eriksson U, Alitalo K: Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 237: 41-57, 1999
91. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 13: 9-22, 1999
92. Tallquist MD, Soriano P, Klinghoffer RA: Growth factor signaling pathways in vascular development. Oncogene 18: 7917-7932, 1999
93. Gale NW, Yancopoulos GD: Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13: 1055-1066, 1999
94. Carmeliet P, Collen D: Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol 237: 133-158, 1999
95. Cheng N, Brantley DM, Chen J: The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 13: 75-85, 2002
96. Bruckner K, Pasquale EB, Klein R: Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 275: 1640-1643, 1997
97. Holland SJ, Gale NW, Mbamalu G, Yancopoulos GD, Henkemeyer M, Pawson T: Bidirectional signaling through the EPH-family receptor Nuk and its transmembrane ligands. Nature 383: 722-725, 1996
98. Lin D, Gish GD, Songyang Z, Pawson T: The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif. J Biol Chem 274: 3726-3733, 1999
99. Torres R, Firestein BL, Dong H, Staudinger J, Olson EN, Huganir RL, Bredt DS, Gale NW, Yancopoulos GD: PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors and their ephrin ligands. Neuron 21: 1453-1463, 1998
100. Adams RH, Wilkinson GA, Weiss C. Diella F, Gale NW, Deutsch U, Risau W, Klein R: Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13: 295-306, 1999
101. Gerety SS, Wang HU, Chen ZF, Anderson DJ: Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4: 403-414, 1999
102. Wang HU, Chen ZF, Anderson DJ: Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93: 741-753, 1998
103. Holzman LB, Marks RM, Dixit VM: A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol 10: 5830-5838, 1990
104. McBride JL, Ruiz JC: Ephrin-A1 is expressed at sites of vascular development in the mouse. Mech Dev 77: 201-204, 1998
105. Myers C, Charboneau A, Boudreau N: Homeobox B3 promotes capillary morphogenesis and angiogenesis. J Cell Biol 148: 343-351, 2000
106. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM: Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 268: 567-569, 1995
107. Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F: A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238: 1717-1720, 1987
108. Maru Y, Hirai H, Yoshida MC, Takaku F: Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph. Mol Cell Biol 8: 3770-3776, 1988
109. Maru Y, Hirai H, Takaku F: Overexpression confers an oncogenic potential upon the eph gene. Oncogene 5: 445-447, 1990
110. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB: The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 6043-6052, 2000
111. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 7011-7026, 2002
112. Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J: Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1: 2-11, 2002
113. Alarcon RM, Denko NC, Giaccia AJ: Genetic determinants that influence hypoxia-induced apoptosis. In Causes and Consequences of Acidic pH in tumors. Goode J, ed. London, England, Novartis Found Symp, 2001, pp. 115-128
114. Maecker H, Yun Z, Giaccia A: Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2: 139, 2002
115. Azhar G, Liu L, Zhang X, Wei JY: Influence of age on hypoxia/ reoxygenation-induced DNA fragmentation and bcl-2, bcl-xl, bax and fas in the rat heart and brain. Mech aging Dev 112: 5-25, 1999
116. Saikumar P, Dong Z, Patel Y, Hall K, Hopfer U, Weinberg JM, Venkatachalam MA: Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury. Oncogene 17: 3401-3415, 1998
117. Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS, Kay M, Winn R, Harlan J: Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem 274: 8039-8045, 1999
118. Tamatani M, Mitsuda N, Matsuzaki H, Okado H, Miyake S, Vitek MP, Yamaguchi A, Tohyama M: A pathway of neuronal apoptosis induced by hypoxia/reoxygenation: Roles of nuclear factor-kappaB and Bcl-2. J Neurochem 75: 683-693, 2000
119. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L: PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100: 1931-1936, 2003
120. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, Adams JM, Strasser A: p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038, 2003
121. Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M, Giaccia A: Regulation of p53 by hypoxia: Dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21: 1297-1310, 2001
122. Bruick RK: Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 97: 9082-9087, 2000
123. Kim JY, Ahn HJ, Ryu JH, Suk K, Park JH: BH3-only Protein Noxa Is a Mediator of Hypoxic Cell Death Induced by Hypoxia-inducible Factor 1α. J Exp Med 199: 113-124, 2004
124. Ray R, Chen G, Vande Velde C, Cizeau J, Park JH, Reed JC, Gietz RD, Greenberg AH: BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem 275: 1439-1448, 2000
125. Vande Velde C, Cizeau J, Dubik D, Alimonti J, Brown T, Israels S, Hakem R, Greenberg AH: BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 20: 5454-5468, 2000
126. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88-91, 1996
127. Maxwell SA, Davis GE: Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. Proc Natl Acad Sci USA 97: 13009-13014, 2000
128. Vousden KH: p53: Death star. Cell 103: 691-694, 2000
129. Semenza GL, Roth PH, Fang H-M, Wang GL: Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269: 23757-23767, 1994
130. Ebert BL, Gleadle JM, O'Rourke JF, Bartlett SM, Poulton J, Ratcliffe PJ: Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: Similarities with the regulation of erythropoietin. Biochem J 313(Pt 3): 809-814, 1996
131. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537, 1996
132. Ebert BL, Firth JD, Ratcliffe PJ: Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 270: 29083-29089, 1995
133. O'Rourke JF, Pugh CW, Bartlett SM, Ratcliffe PJ: Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur J Biochem 241: 403-410, 1996
134. Graven KK, McDonald RJ, Farber HW: Hypoxic regulation of endothelial glyceraldehyde-3-phosphate dehydrogenase. Am J Physiol 274: C347-355, 1998
135. Riddle SR, Ahmad A, Ahmad S, Deeb SS, Malkki M, Schneider BK, Allen CB, White CW: Hypoxia induces hexokinase II gene expression in human lung cell line A549. Am J Physiol Lung Cell Mol Physiol 278: L407-416, 2000
136. Salceda S, Beck I, Caro J: Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia. Arch Biochem Biophys 334: 389-394, 1996
137. Leonard MO, Cottell DC, Godson C, Brady HR, Taylor CT: The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. J Biol Chem 278: 40296-40304, 2003
138. Discher DJ, Bishopric NH, Wu X, Peterson CA, Webster KA: Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem 273: 26087-26093, 1998
139. Denko N, Schindler C, Koong A, Laderoute K, Green C, Giaccia A: Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res 6: 480-487, 2000
140. Niitsu Y, Hori O, Yamaguchi A, Bando Y, Ozawa K, Tamatani M, Ogawa S, Tohyama M: Exposure of cultured primary rat astrocytes to hypoxia results in intracellular glucose depletion and induction of glycolytic enzymes. Brain Res Mol Brain Res 74: 26-34, 1999
141. Kawaguchi T, Veech RL, Uyeda K: Regulation of energy metabolism in macrophages during hypoxia. Roles of fructose 2,6-bisphosphate and ribose 1,5-bisphosphate. J Biol Chem 276: 28554-28561, 2001
142. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158: 905-919, 2001
143. Mukhopadhyay CK, Mazumder B, Fox PL: Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 275: 21048-21054, 2000
144. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE: Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the erythropoietin gene. Proc Natl Acad Sci USA 88: 5680-5684, 1991
145. Smith JJ, O'Brien-Ladner AR, Kaiser CR, Wesselius LJ: Effects of hypoxia and nitric oxide on ferritin content of alveolar cells. J Lab Clin Med 141: 309-317, 2003
146. Yang ZZ, Zou AP: Transcriptional regulation of heme oxygenases by HIF-1α in renal medullary interstitial cells. Am J Physiol Renal Physiol 281: F900-908, 2001
147. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G: Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 274: 24142-24146, 1999
148. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U, Alitalo K: Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14: 2475-2483, 1997
149. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992
150. Plate KH, Breier G, Millauer B, Ullrich A, Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Research 53: 5822-5827, 1993
151. Gleadle JM, Ebert BL, Firth JD, Ratcliffe PJ: Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol 268: C1362-1368, 1995
152. Mandriota SJ, Pepper MS: Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 83: 852-859, 1998
153. Kourembanas S, McQuillan LP, Leung GK, Faller DV: Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 92: 99-104, 1993
154. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L: A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promotor. J Exp Med 182: 1683-1693, 1995
155. Tenan M, Fulci G, Albertoni M, Diserens AC, Hamou MF, El Atifi-Borel M, Feige JJ, Pepper MS, Van Meir EG: Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 191: 1789-1798, 2000
156. Vasir B, Reitz P, Xu G, Sharma A, Bonner-Weir S, Weir GC: Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-alpha, TGF-beta, bFGF and Vimentin) in cultured and transplanted rat islets. Diabetologia 43: 763-772, 2000
157. Schaffer L, Scheid A, Spielmann P, Breymann C, Zimmermann R, Meuli M, Gassmann M, Marti HH, Wenger RH: Oxygen-regulated expression of TGF-beta 3, a growth factor involved in trophoblast differentiation. Placenta 24: 941-950, 2003
158. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138-1143, 2003
159. Willam C, Koehne P, Jurgensen JS, Grafe M, Wagner KD, Bachmann S, Frei U, Eckardt KU: Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ Res 87: 370-377, 2000
160. Grilli A, De Lutiis MA, Patruno A, Speranza L, Cataldi A, Centurione L, Taccardi AA, Di Napoli P, De Caterina R, Barbacane R, Conti P, Felaco M: Effect of chronic hypoxia on inducible nitric oxide synthase expression in rat myocardial tissue. Exp Biol Med (Maywood) 228: 935-942, 2003
161. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, Lewis CE: Hypoxia-induced gene expression in human macrophages: Implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 163: 1233-1243, 2003
162. Suzuma K, Takagi H, Otani A, Honda Y: Hypoxia and vascular endothelial growth factor stimulate angiogenic integrin expression in bovine retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci 39: 1028-1035, 1998
163. Pinsky DJ, Liao H, Lawson CA, Yan SF, Chen J, Carmeliet P, Loskutoff DJ, Stern DM: Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 102: 919-928, 1998
164. Graham CH, Fitzpatrick TE, McCrae KR: Hypoxia stimulates urokinase receptor expression through a heme-dependent pathway. Blood 91: 3300-3307, 1998
165. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001
166. Tazuke SI, Mazure NM, Sugawara J, Carland G, Faessen GH, Suen LF, Irwin JC, Powell DR, Giaccia AJ, Giudice LC: Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: A possible model for IGFBP-1 expression in fetal hypoxia. Proc Natl Acad Sci USA 95: 10188-10193, 1998
167. Ozawa K, Tsukamoto Y, Hori O, Kitao Y, Yanagi H, Stern DM, Ogawa S: Regulation of tumor angiogenesis by oxygen-regulated protein 150, an inducible endoplasmic reticulum chaperone. Cancer Res 61: 4206-4213, 2001
168. Roll DE, Murphy BJ, Laderoute KR, Sutherland RM, Smith HC: Oxygen regulated 80 kDa protein and glucose regulated 78 kDa protein are identical. Mol Cell Biochem 103: 141-148, 1991
169. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E, Keshet E: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 394: 485-490, 1998
170. Kraggerud SM, Sandvik JA, Pettersen EO: Regulation of protein synthesis in human cells exposed to extreme hypoxia. Anticancer Res 15: 683-686, 1995
171. Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW: Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem 270: 27752-27757, 1995
172. Baek SH, Lee UY, Park EM, Han MY, Lee YS, Park YM: Role of protein kinase Cdelta in transmitting hypoxia signal to HSF and HIF-1. J Cell Physiol 188: 223-235, 2001
173. Saarikoski ST, Rivera SP, Hankinson O: Mitogen-inducible gene 6 (MIG-6), adipophilin and tuftelin are inducible by hypoxia. FEBS Lett 530: 186-190, 2002
174. Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, Livingston DM: Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev 13: 64-75, 1999
175. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K, Sato Y: Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 289: 39-43, 2001
176. Muller JM, Krauss B, Kaltschmidt C, Baeuerle PA, Rupee RA: Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway. J Biol Chem 272: 23435-23439, 1997
177. Ausserer WA, Bourrat-Floeck B, Green CJ, Laderoute KR, Sutherland RM: Regulation of c-jun expression during hypoxic and low-glucose stress. Mol Cell Biol 14: 5032-5042, 1994
178. Koong AC, Chen EY, Giaccia AJ: Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 54: 1425-1430, 1994
179. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL: HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 61: 6669-6673, 2001
180. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL: Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59: 3915-3918, 1999
181. Matsui H, Ihara Y, Fujio Y, Kunisada K, Akira S, Kishimoto T, Yamauchi-Takihara K: Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes. Cardiovasc Res 42: 104-112, 1999
182. Berger AP, Kofler K, Bektic J, Rogatsch H, Steiner H, Bartsch G, Klocker H: Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57: 57-65, 2003
183. Furuta GT, Turner JR., Taylor CT, Hershberg RM, Comerford K, Narravula S, Podolsky DK, Colgan SP: Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med 193: 1027-1034, 2001